ECEve M. Carter

Eve M. Carter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eve M. Carter has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Idler Compounds: A Simple Protocol for Openly Sharing Fridge Contents for Cross-Screening

    by Rebecka Isaksson, Eve M. Carter, Charlotte K. Hind, J. Mark Sutton, Hazel Rudgyard, Adam H. Roberts, Christopher W. Moon, Yinuo Wang, Sandra Codony, Antón L. Martínez, et al.

    Academic drug discovery laboratories tend to accumulate collections of compounds with great potential value that merely reside in fridges and freezers. Cross screening these libraries against alternative targets holds significant potential for uncovering novel hits, but in the academic setting compound collections are rarely used, and shared, in this way. We present a short guide for collecting small molecules not being actively pursued in group projects (which we term "idlers") to establish an open compound library. We describe how a diverse subset of this library was screened against a panel of pathogens, with the resulting data made publicly available. We hope to encourage other academic groups to develop and share their own libraries of idlers, thereby maximizing the utility of existing resources, enabling new insights, and catalyzing novel research directions through open science.

  • Open Access

    Idler Compounds: A Simple Protocol for Openly Sharing Fridge Contents for Cross-Screening

    by Rebecka Isaksson, Eve Carter, Charlotte Hind, J. Mark Sutton, Hazel Rudgyard, Adam H. Roberts, Christopher W. Moon, Yinuo Wang, Todd Group Researchers, Sandra Codony, et al.

    The first step in discovering novel medicines is identifying an initial hit against a biological target or organism, followed by extensive iterative processes to explore the structure-activity relationship and establish a lead compound. As a result, drug discovery laboratories tend to accumulate extensive collections of compounds with great potential value that merely reside in fridges and freezers. Cross screening these libraries against alternative targets holds significant potential for uncovering novel hits, but in the academic setting compound collections are rarely used in this way. We present a short guide for collecting small molecules not being actively pursued in group projects (which we term “idlers”) to establish an open compound library. We describe how a diverse subset of this library was screened against a panel of pathogens, with the resulting data made publicly available. We hope this work encourages other academic drug discovery groups to develop and share their own libraries of idlers, thereby maximising the utility of existing resources, enabling new insights, and catalysing novel research directions through open science.

  • Open Access

    ABHD2 activity is not required for the non-genomic action of progesterone on human sperm

    by Madison Edwards, Alexandra Amaral, Eve M. Carter, Oliver Arnolds, Karen Vester, Anna Thrun, Edvard Wigren, Evert Homan, Pauline Ribera, Kirsty Bentley, et al.

    Study question: Is the hydrolase ABHD2 required for progesterone-induced Ca 2+ influx via CatSper and the resulting motility responses in human sperm? Summary answer: Progesterone-induced Ca 2+ influx via CatSper and the resulting motility responses in human sperm do not require ABHD2 activity. What is known already: Sperm motility is tightly regulated by signalling pathways that are activated as sperm ascend the female reproductive tract, including progesterone triggering Ca 2+ influx via the CatSper channel and inducing hyperactivated motility needed for fertilization. This process is thought to involve ABHD2, which may hydrolyse the endogenous CatSper inhibitor 2-arachidonoylglycerol (2-AG), thereby relieving inhibition and enabling calcium entry into the flagellum. Study design, size, duration: Potent small molecule inhibitors of ABHD2 activity were synthesized, characterized, and used as tools to scrutinize the role of ABHD2 in activation of CatSper and regulation of sperm motility. Participants/materials, setting, methods: Derivatives of published ABHD2 inhibitors were optimised for in vitro potency and cellular activity and subsequently tested in human sperm motility and Ca 2+ influx assays. Main results and the role of chance: Progesterone does not activate ABHD2 in vitro. In addition, inhibition of ABHD2 in human sperm has no effect on progesterone-induced Ca 2+ influx through CatSper nor on basal or progesterone-induced hyperactivated motility. This demonstrates that ABHD2 activity is, in fact, not required for the non-genomic action of progesterone on human sperm. Large scale data: none Limitations, reasons for caution: We examined the effects of inhibition of the enzymatic activity of ABHD2. We cannot exclude that ABHD2 functions as a part of a larger multiprotein complex, in which it may play a structural role independent of its hydrolase activity. Wider implications of the findings: This study presents conclusive evidence that ABHD2 does not bind progesterone and that its hydrolase activity is not required for progesterone activation of CatSper and resulting changes in motility of human sperm. These results highlight the need for further research to elucidate the mechanism underlying the non-genomic action of progesterone on human sperm. Study funding/competing interest(s): This publication is based on research funded by the Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Gates Foundation. LT, CB, and TS were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - project numbers 329621271 (CRU326; CB, TS), and 404595355 (Research Training Group “Chemical biology of ion channels (Chembion)’; LT, TS). This work was funded by the German Federal Ministry of Education and Research (BMBF) within the framework of Contraception Research, grant number 01GR2501A and 01GR2502A. A.A., K.V., A.T., N.D., A.H., M.W. and R.L. are employees of Nuvisan ICB GMBH, Berlin, Germany. Nuvisan is recipient of a Gates Foundation grant. A.A is associate editor of Human Reproduction Open.

  • Open Access

    Expanding the Substrate Scope of N‐ and O‐Methyltransferases from Plants for Chemoselective Alkylation**

    by Emely Jockmann, Fabiana Subrizi, Michael K. F. Mohr, Eve M. Carter, Pia M. Hebecker, Désirée Popadić, Helen C. Hailes, Jennifer N. Andexer

    Methylation reactions are of significant interest when generating pharmaceutically active molecules and building blocks for other applications. Synthetic methylating reagents are often toxic and unselective due to their high reactivity. S‐Adenosyl‐l‐methionine (SAM)‐dependent methyltransferases (MTs) present a chemoselective and environmentally friendly alternative. The anthranilate N‐MT from Ruta graveolens (RgANMT) is involved in acridone alkaloid biosynthesis, methylating anthranilate. Although it is known to methylate substrates only at the N‐position, the closest relatives with respect to amino acid sequence similarities of over 60 % are O‐MTs catalysing the methylation reaction of caffeate and derivatives containing only hydroxyl groups (CaOMTs). In this study, we investigated the substrate range of RgANMT and a CaOMT from Prunus persica (PpCaOMT) using compounds with both, an amino‐ and hydroxyl group (aminophenols) as possible methyl group acceptors. For both enzymes, the reaction was highly chemoselective. Furthermore, generating cofactor derivatives in situ enabled the transfer of other alkyl chains onto the aminophenols, leading to an enlarged pool of products. Selected MT reactions were performed at a preparative biocatalytic scale in in vitro and in vivo experiments resulting in yields of up to 62 %.


  • Open Access

    Expanding the Substrate Scope of N - and O -Methyltransferases from Plants for Chemoselective Alkylation

    by Emely Jockmann, Fabiana Subrizi, Michael K. F. Mohr, Eve M. Carter, Pia M. Hebecker, Désirée Popadić, Helen C. Hailes, Jennifer N. Andexer

    Methylation reactions are of significant interest when generating pharmaceutically active molecules and building blocks for other applications. Synthetic methylating reagents are often toxic and unselective due to their high reactivity. S -Adenosyl-L-methionine (SAM)-dependent methyltransferases (MTs) present a chemoselective and environmentally friendly alternative. The anthranilate N -MT from Ruta graveolens ( Rg ANMT) is involved in acridone alkaloid biosynthesis, methylating anthranilate. Although it is known to methylate substrates only at the N- position, the closest relatives with respect to amino acid sequence similarities of over 60% are O -MTs catalysing the methylation reaction of caffeate and derivatives containing only hydroxyl groups (CaOMTs). In this study, we investigated the substrate range of Rg ANMT and a CaOMT from Prunus persica ( Pp CaOMT) using compounds with both, an amino- and hydroxyl group (aminophenols) as possible methyl group acceptors. For both enzymes, the reaction was highly chemoselective. Furthermore, generating cofactor derivatives in situ enabled the transfer of other alkyl chains onto the aminophenols, leading to an enlarged pool of products. Selected MT reactions were performed at a preparative biocatalytic scale in in vitro and in vivo experiments resulting in yields of up to 62%.

  • Open Access

    Mechanoenzymatic reactions for the hydrolysis of PET

    by Esther Ambrose-Dempster, Leona Leipold, Dragana Dobrijevic, Maria Bawn, Eve M. Carter, Gorjan Stojanovski, Tom D. Sheppard, Jack W. E. Jeffries, John M. Ward, Helen C. Hailes

    Mechanoenzymatic reactions are described for the degradation of different PET materials using whole cell PETases.


  • Open Access

    Enzymatic synthesis of benzylisoquinoline alkaloids using a parallel cascade strategy and tyrosinase variants

    by Yu Wang, Fabiana Subrizi, Eve M. Carter, Tom D. Sheppard, John M. Ward, Helen C. Hailes

    Benzylisoquinoline alkaloid derived pharmaceuticals are widely applied in modern medicines. Recent studies on the microbial production of benzylisoquinolines have highlighted key biological syntheses towards these natural products. Routes to non-natural benzylisoquinolines have been less explored, particularly halogenated compounds which are more challenging. Here, we show the use of a tyrosinase, tyrosine decarboxylase, transaminase, and norcoclaurine synthase which are combined in a parallel cascade design, in order to generate halogenated benzylisoquinoline alkaloids in high enantiomeric excess. Notably, mutagenesis studies are applied to generate tyrosinase mutants, which enhance the acceptance of halogenated tyrosines for use in the biocatalytic cascades developed.


  • Open Access

    Mechanoenzymatic reactions with whole cell transaminases: shaken, not stirred

    by Eve M. Carter, Esther Ambrose-Dempster, John M. Ward, Tom D. Sheppard, Helen C. Hailes

    The use of mechanoenzymatic reaction conditions with whole cell transminases to produce a range of amines in high yields and stereoselectivities.


  • Open Access

    Chemoenzymatic approaches to plant natural product inspired compounds

    by Rebecca Roddan, Eve M. Carter, Benjamin Thair, Helen C. Hailes

    Chemoenzymatic routes to plant natural products and analogues are described, highlighting the advantages of incorporating biocatalysis into synthetic strategies.